SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   SCHEDULE TO

        Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the
                        Securities Exchange Act of 1934
                                (Amendment No. 4)

                           Utah Medical Products, Inc.
                           ---------------------------
                                (Name of Issuer)

                      Utah Medical Products, Inc. (Issuer)
                      ------------------------------------
                            (Name of Filing Persons)

                     Common Stock, Par Value $.01 Per Share
                     --------------------------------------
                         (Title of Class of Securities)

                                    917488108
                      -------------------------------------
                      (Cusip Number of Class of Securities)

                                Kevin L. Cornwell
                                Chairman and CEO
                           Utah Medical Products, Inc.
                               7043 South 300 West
                               Midvale, Utah 84047
                                 (801-566-1200)
  ----------------------------------------------------------------------------
  (Name, address and telephone numbers of person authorized to receive notices
                and communications on behalf of filing persons)

                            CALCULATION OF FILING FEE

  Transaction Valuation*                                 Amount of Filing Fee
       $8,200,000                                              $1,640

*  Calculated  solely for the  purpose of  determining  the amount of the filing
   fee,  based on the purchase of 1,000,000  shares of Common  Stock,  par value
   $.01 per share, at the tender offer price of $8.20 per share.

[X]      Check  the box if any part of the fee is  offset  as  provided  by Rule
         0-11(a)(2)  and identify the filing with which the  offsetting  fee was
         previously paid. Identify the previous filing by registration statement
         number, or the Form or Schedule and the date of its filing.

Amount Previously Paid:  $1,640
Filing Party:  Utah Medical Products, Inc.
Form or Registration No.:  Amendment No. 1 to Schedule TO
Date Filed:  August 18, 2000

[ ] Check the box if the filing  relates  solely to  preliminary  communications
made before the commencement of a tender offer.

Check the  appropriate  boxes below to designate  any  transaction  to which the
statement relates:

[ ]      third-party tender offer subject to Rule 14d-1.
[x]      issuer tender offer subject to Rule 13e-4.
[ ]      going-private transaction subject to Rule 13e-3
[ ]      amendment to Schedule 13D under Rule 13d-2

Check the following box if the filing is a final amendment reporting the results
of the tender offer: [ ]


     This  Amendment No. 4 to the Tender Offer  Statement on Schedule TO relates
to the tender offer by Utah Medical Products,  Inc., a Utah corporation  ("UTMD"
or the "Company"), to purchase 1,000,000 shares, or such lesser number of shares
as are validly  tendered and not withdrawn,  of its Common Stock, par value $.01
per share, including the associated common stock purchase rights issued pursuant
to the Rights  Agreement,  dated as of October 28,  1994,  between  Utah Medical
Products, Inc. and Registrar and Transfer Company as Rights Agent, at a price of
$8.20 per Share,  upon the terms and subject to the  conditions set forth in the
Offer to Purchase  dated August 18, 2000 (the "Offer to  Purchase"),  and in the
related Letter of Transmittal  which,  as they may be amended from time to time,
together  constitute  the  "Offer,"  copies of which  were  previously  filed on
Amendment  No.  1 to  the  Schedule  TO  as  Exhibit  (a)(1)(A)  and  (a)(1)(B),
respectively. This Amendment No. 4 to the Schedule TO is intended to satisfy the
reporting  requirements  of Rule  13e-4(c)(1) of the Securities  Exchange Act of
1934, as amended.


Item 12.   Exhibits.

(a)(5)(D)  Form of Press Release issued by the Company dated September 19, 2000.


                                    SIGNATURE

         After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.


                                            UTAH MEDICAL PRODUCTS, INC.


                                   By:      /s/ KEVIN L. CORNWELL
                                            ------------------------------------
                                   Name:    Kevin L. Cornwell
                                   Title:   Chairman and Chief Executive Officer

Dated: September 19, 2000



                                  EXHIBIT INDEX


 Exhibit #            Description
- -------------         -----------
(a)(5)(D)             Press Release, dated September 19, 2000






                               EXHIBIT (a) (5) (D)

                                  PRESS RELEASE
                      UTMD Announces Results of Self-Tender

Contact:  Paul Richins                                        September 19, 2000
(801) 566-1200

Salt Lake City, Utah - Utah Medical Products,  Inc.'s (Nasdaq:UTMD) Tender Offer
for  1,000,000 of its Shares at $8.20 per share,  initially  announced on August
10,  expired  at 5:00 p.m.  Eastern  Time  Friday  September  15.  According  to
preliminary results tabulated by Registrar and Transfer Company,  the Depositary
for the Offer, which need final  verification,  shareholders  tendered 1,607,000
shares.

In  accordance  with the  applicable  regulations  of the SEC,  which  allow the
Company to purchase  pursuant to the Offer an additional amount of shares not to
exceed 2% of UTMD's outstanding  shares, UTMD will purchase 100% of the odd lots
and 69% of all other shares  tendered,  or about  1,120,000  total shares.  UTMD
estimates  that  proceeds will be  distributed  to selling  shareholders  by the
Depositary in about two weeks' time.

After the Offer, UTMD's outstanding shares will number approximately  5,034,000.
Given  UTMD's  ability  to  generate  cash  from its  operations,  the  Board of
Directors is pleased to have the opportunity to repurchase  shares at such a low
value,  and remains  committed to increasing  shareholder  value with an ongoing
share repurchase  program.  Shareholders who did not tender their shares now own
21% more of UTMD than they did before the Offer expired.

CEO Kevin  Cornwell  states,  "This year has obviously been a difficult year for
UTMD in terms of sustaining its top line sales growth. In the U.S.,  competition
has been keen in our core product  areas and  hospitals  have been  increasingly
constrained in their ability to buy premium products; and overseas, the strength
of the  dollar  has  impeded  business  activity.  We  believe  external  market
conditions  will improve,  and in addition,  look forward to introduction of new
products from internal product  development,  and the possibility of finding and
successfully  completing an accretive acquisition.  Despite the recent period of
slower sales, UTMD remains very profitable and  operationally  fit. I believe we
will  begin  to  renew  UTMD's  sales  growth,   with  the  resulting  improving
performance  together with the share  repurchases  generating more interest from
investors looking for excellent stock values."

Investors  are  cautioned  that this  press  release  contains  forward  looking
statements and that actual events may differ from those projected. Risks factors
that could  cause  results to differ  materially  from those  projected  include
market  acceptance of products,  timing of regulatory  approval of new products,
UTMD's ability to efficiently manufacture,  market, and sell its products, among
other factors that have been outlined in UTMD's public  disclosure  filings with
the SEC.